Relay Therapeutics (RLAY) Preferred Shares (2019)

Relay Therapeutics' (RLAY) quarterly Preferred Shares came in at $537.8 million in Q4 2019.

Relay Therapeutics (RLAY) Preferred Shares (2019) Analysis & Trends

Relay Therapeutics (RLAY) has 1 years of Preferred Shares data on file, last reported at $537.8 million in Q4 2019.

On a quarterly basis, Preferred Shares changed N/A year-over-year to $537.8 million in Q4 2019; TTM through Dec 2019 was $537.8 million, a N/A change from a year earlier, with the FY2019 full-year figure at $537.8 million, changed N/A from the prior year.
Preferred Shares for Q4 2019 stood at $537.8 million.
Over the last five years, Preferred Shares for RLAY reached as high as $537.8 million in Q4 2019 and fell as low as $537.8 million in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Shares (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Relay Therapeutics	3.43 Bn	3.43 Bn	-	-

Download Data

Date	Value
Dec 31, 2019	537.78 Mn